6.3. predictive markers. 6.3.1. clinical histopathological markers based retrospective data only, patients secondary mibc worse response nac compared patients primary mibc . pietzak et al., retrospectively analysed clinico-pathologic outcomes comparing 245 patients clinical t2–4a n0m0 primary mibc 43 patients secondary mibc treated nac rc. found patients secondary mibc lower pathologic response rates following nac primary mibc (univariable 26% vs. 45%, multivariable or: 0.4 [95% ci: 0.18–0.84, p = 0.02]). also found mibc patients progressing nac worse css compared patients treated cystectomy alone (p = 0.002). subtypes non-uc also linked worse outcomes nac, is, yet, insufficient data conclude considered predictive markers . 6.3.2. molecular markers several predictive biomarkers investigated serum vascular endothelial growth factor (vegf) , circulating tumour cells, immune stromal signatures, well expression defects dna damage repair (ddr) genes including ercc2, atm, mre11, rb1 fancc may predict response cisplatin-based nac chemoradiation [230-233]. recently, alterations fgfr2/3 including mutations gene fusions shown associated response fgfr inhibitors . recent efforts focused markers predicting response immune checkpoint inhibition. programmed death-ligand 1 (pd-l1) expression immunohistochemistry evaluated several studies mixed results may part related use different antibodies various scoring systems evaluating different compartments, i.e., tumour cells, immune cells, both. major limitation pd-l1 staining relates significant proportion pd-l1-negative patients respond immune checkpoint blockade. example, imvigor 210 phase ii study atezolizumab patients advanced/metastatic uc progressed platinum-based chemotherapy, responses seen 18% patients low/no pd-l1 expression . present, indication pd-l1 testing relates use immune checkpoint inhibitors monotherapy patients locally-advanced metastatic uc unfit cisplatin-containing chemotherapy received prior therapy. setting, atezolizumab (the european medicines agency [ema] approval) pembrolizumab (ema approval) used patients unfit cisplatin-containing chemotherapy whose tumours overexpress pd-l1 (i.e., case atezolizumab; tumour-infiltrating immune cells [ic] covering ≥ 5% tumour area using sp142 assay; case pembrolizumab, combined positive score (cps) ≥ 10 using dako 22c33 platform) . fda revised label pembrolizumab patients advanced uc approval first line patients eligible platinum-based chemotherapy, however, irrespective pd-l1 status. urothelial cancer associated high tumour mutational burden (tmb) . predicted neoantigen burden tmb associated response immune checkpoint blockade several malignancies. high tmb associated response immune checkpoint inhibitors metastatic bc . conflicting results seen studies evaluating immune checkpoint inhibitors neoadjuvant setting pembrolizumab neoadjuvant therapy radical cystectomy patients muscle- invasive urothelial bladder carcinoma (pure)-01 study demonstrating association high tmb response association atezolizumab phase ii study investigating safety efficacy neoadjuvant atezolizumab mibc (abacus) . markers evaluated predicting response immune checkpoint inhibitors include molecular subtypes discussed earlier, cd8 expression immunohistochemistry immune gene cell signatures. recent work focused importance stroma including role transforming growth factors (tgfs) predicting response immune checkpoint blockade . powles et al., reported potential ctdna guide use adjuvant io uc . 581 patients phase iii rct adjuvant atezolizumab vs. observation uc, ctdna testing start therapy identified 214 (37%) patients positive ctdna poor prognosis (observation arm hr = 6.3, 95% ci: 4.45–8.92; p < 0.0001). patients positive ctdna improved dfs os atezolizumab arm vs. observation arm (dfs: hr = 0.58 [95% ci: 0.43–0.79]; p = 0.0024, os: hr = 0.59 [95% ci: 0.41–0.86]). difference dfs os treatment arms patients negative ctdna. rate ctdna clearance week 6 higher atezolizumab arm (18%) observation arm (4%) (p = 0.0204). ongoing clinical trial (imvigor011) evaluating atezolizumab adjuvant therapy patients high-risk mibc ctdna positive following cystectomy . exploratory analysis patients metastatic uc received pembrolizumab first-line (keynote-052 trial) salvage (keynote-045 trial) settings, demonstrated tmb t-cell inflammed gene expression profile significantly associated improved outcomes, however pd-l1 associated improved outcomes stromal signature worse outcomes keynote-052, keynote-045 suggesting biomarkers may perform differently different clinical disease states i.e. first line versus salvage settings . second study, scoring system (cpt) based cd39, pd-l1 tmb shown predict response pd-l1 blockade platinum-based chemotherapy patients mibc . although promising, currently validated predictive molecular markers routinely used clinical practice. validation studies awaited.